A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.

NCT02663752 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

PROCEDURE: Bone marrow aspirate
DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals